Skip to content

BioToChina.org

BioToChina.org is the first organization to connect Pharma, Biotech & Medtech BDs in China and the rest of the world.

  • ACCESS ASIA
  • ACCESS ASIA Spring BD Salon & Reception 2026
  • Agenda
  • Register

biotochina

biotochina
Uncategorized

Vol.59, 2025 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报

by biotochina28th July 2025
Continue Reading
Uncategorized

Vol.58, 2025 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报

by biotochina28th July 2025
Continue Reading
Uncategorized

Vol.57, 2025 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报

by biotochina17th July 2025
Continue Reading
Uncategorized

YAFO Client | Breakthrough for Next-Generation TRK Inhibitor: Jiangsu Vcare’s New Anti-tumor Drug, Eratrectinib (VC004) Capsules, Receives NDA Acceptance

by biotochina14th July 2025
Continue Reading
Uncategorized

Protected: YAFO Client | Breakthrough for Next-Generation TRK Inhibitor: Jiangsu Vcare’s New Anti-tumor Drug, Eratrectinib (VC004) Capsules, Receives NDA Acceptance

by biotochina7th July 20257th July 2025
Continue Reading
Uncategorized

2025 June-YAFO Global Biopharma Transactions Report 雅法全球生物医药交易月报

by biotochina5th July 2025
Continue Reading

Posts navigation

Older posts
Newer posts

BioToChina.org

BioToChina.org is the first organization to connect Pharma, Biotech & Medtech BDs in China and the rest of the world.

Powered by Tech-Discovery

Blog at WordPress.com.
  • Subscribe Subscribed
    • BioToChina.org
    • Already have a WordPress.com account? Log in now.
    • BioToChina.org
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar
 

Loading Comments...